deltatrials
Completed OBSERVATIONAL NCT02426333

Optimizing Abiraterone Therapy (OPTIMUM)

Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker - Drug Exposure - as a Predictor for Drug Response in Patients With mCRPC

Sponsor: Janssen-Cilag Ltd.

Conditions Metastatic Castration Resistant Prostate Cancer
Interventions Abiraterone Acetate
Updated 17 times since 2017 Last updated: Sep 12, 2019 Started: Jan 31, 2016 Primary completion: Apr 24, 2019 Completion: Aug 1, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02426333, this observational or N/A phase trial focuses on Metastatic Castration Resistant Prostate Cancer and remains completed. Sponsored by Janssen-Cilag Ltd., it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Apr 2017 · 3 months · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Oct 2019 · 8 months · monthly snapshot~Oct 2019 – ~Sep 2020 · 11 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Mar 2022 — Jul 2024 [monthly]

    Completed

  5. Dec 2021 — Mar 2022 [monthly]

    Completed

▶ Show 12 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed

  2. Nov 2020 — Jan 2021 [monthly]

    Completed

  3. Sep 2020 — Nov 2020 [monthly]

    Completed

  4. Oct 2019 — Sep 2020 [monthly]

    Completed

    Status: Recruiting → Completed

  5. Feb 2019 — Oct 2019 [monthly]

    Recruiting

  6. Jun 2018 — Feb 2019 [monthly]

    Recruiting

  7. May 2018 — Jun 2018 [monthly]

    Recruiting

  8. Apr 2018 — May 2018 [monthly]

    Recruiting

    Phase: NA → None

  9. Aug 2017 — Apr 2018 [monthly]

    Recruiting NA

  10. Jun 2017 — Aug 2017 [monthly]

    Recruiting NA

  11. Apr 2017 — Jun 2017 [monthly]

    Recruiting NA

    Phase: PHASE1_PHASE2 → NA

  12. Jan 2017 — Apr 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen-Cilag Ltd.
  • Radboud University Medical Center
Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations